Novo Nordisk AS - Company Profile
Powered by 
All the sales intelligence you need on Novo Nordisk AS in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Novo Nordisk AS fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Novo Nordisk AS.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
View more- Top 10 Pharmaceutical Companies in Europe in 2022 by Market Capitalization
- Top 10 Big Biopharma Companies (Large Pharma & Large Biotech) in Europe in 2021 by Revenues
- Top 10 Pharma Companies in Europe in 2021 by R&D Expenditure
- Top 10 Pharmaceutical Companies in the World in 2022 by Market Capitalization
Novo Nordisk AS (Novo Nordisk), is a healthcare company focused on discovering, developing, and delivering biological medicines for therapy areas for diabetes, haemophilia, human growth hormone (HGH) disorders, rare blood and rare endocrine diseases, and obesity. The company offers insulin products such as Tresiba, Levemir, and NovoRapid, as well as GLP-1 receptor agonists like Ozempic and Victoza. Novo Nordisk also provides haemophilia treatments like NovoSeven and growth hormone therapies such as Norditropin. Its products include pre-filled delivery systems for insulin, glucagon hypokit, cartridge, needles, vials, insulin, estradiol for hormone replacement, recombinant drugs for haemophilia, glucagon, and oral antidiabetic agents. The company offers its products to patients through brands such as NovoPen, FlexPen, Saxenda, and Ozempic. It markets products through subsidiaries in North America, Europe, Asia, Latin America, Africa, the Middle East, and Australia. Novo Nordisk is headquartered in Bagsvaerd, Denmark.
Headquarters
Denmark
Address
Novo Alle 1, Bagsvaerd, 2880
Website
www.novonordisk.com
Telephone
45 444 48888
No of Employees
64,974
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
NOVO B (CPH)
Revenue (2024)
$46.7B
6.4%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
1.4%
(2024 vs 2023)
Market Cap*
$170.0B
Net Profit Margin (2024)
XYZ
-4.7%
(2024 vs 2023)
* As of and is in US$
Novo Nordisk AS premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| - | - |
| Diabetes Delivery Systems: | Rivfloza |
| Injection Needles | Tresiba |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In June, the company signed a strategic partnership with NOVI Health to offer greater access to physician-led, structured weight loss programs. |
| 2026 | Financing Agreements | In June, the company announced the investment of more than CZK 8 billion in its manufacturing facility in Bohumil, Central Bohemia. |
| 2026 | Plans/Strategy | In June, the company announced plans to launch Novogene (insulin smegglutide injection) in China for adults with type 2 diabetes with inadequate control on basal insulin or GLP‑1 RA therapy. |
Competitor Comparison
| Key Parameters | Novo Nordisk AS | Eli Lilly and Co | Merck & Co Inc | Pfizer Inc | AstraZeneca Plc |
|---|---|---|---|---|---|
| Headquarters | Denmark | United States of America | United States of America | United States of America | United Kingdom |
| City | Bagsvaerd | Indianapolis | Rahway | New York City | Cambridge |
| State/Province | - | Indiana | New Jersey | New York | Cambridgeshire |
| No. of Employees | 64,974 | 50,605 | 75,000 | 75,000 | 96,100 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Lars Rebien Sorensen | Chairman | Executive Board | 2025 | 72 |
| Cees de Jong | Vice Chairman | Executive Board | 2025 | 65 |
| Maziar Mike Doustdar | President; Chief Executive Officer | Senior Management | 2025 | 56 |
| Karsten Munk Knudsen | Chief Financial Officer; Executive Vice President | Senior Management | 2018 | 55 |
| Martin Holst Lange | Executive Vice President; Chief Scientific Officer | Senior Management | 2025 | 56 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer